Avecho Biotechnology (ASX:AVE) said it has received AU$1.98 million for the year ended Dec. 31, 2025, under the Australian Government's research and development tax incentive scheme, according to a Friday Australian bourse filing.
The company said AU$1.62 million of the funds will be used to repay Endpoint Capital for advances on the company's R&D tax credit paid over the past year, with the remainder to support operations and advance its commercialization strategy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.